Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis
Eur J Cancer
.
2019 May:113:72-74.
doi: 10.1016/j.ejca.2019.03.006.
Epub 2019 Apr 12.
Authors
Billal Tedbirt
1
,
Michel De Pontville
2
,
Pierre Branger
3
,
Camille Picard
2
,
Barouyr Baroudjian
4
,
Céleste Lebbé
5
,
Antoine F Carpentier
6
,
Julie Delyon
5
;
PATIO group
Affiliations
1
Department of Dermatology, Rouen University Hospital, Rouen, France. Electronic address: billal.tedbirt@etu.univ-rouen.fr.
2
Department of Dermatology, Caen University Hospital, Caen, France.
3
Department of Neurology, Caen University Hospital, Caen, France.
4
Department of Dermatology, APHP Saint Louis Hospital, Paris, France.
5
Department of Dermatology, APHP Saint Louis Hospital, Paris, France; Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France.
6
Université Paris 7 Diderot, Sorbonne Paris Cité, Paris, France; Department of Neurooncology, APHP Saint Louis Hospital, Paris, France.
PMID:
30986705
DOI:
10.1016/j.ejca.2019.03.006
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Myasthenia Gravis*
Myositis*
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab